Table 1.
Patient and Tumor Characteristics
| 0229 (n=39) | 0839 (n=54) | Total (n=93) | |
|---|---|---|---|
| Age | |||
| Median | 58 | 60.5 | 60 |
| Min - Max | 41 - 75 | 32 - 78 | 32 - 78 |
| Q1 - Q3 | 53 - 64 | 54 - 67 | 53 - 65 |
| Gender | |||
| Male | 23 (59.%) | 30 (56%) | 53 (57%) |
| Female | 16 (41.%) | 24 (44%) | 40 (43%) |
| Race | |||
| White | 30 (77%) | 49 (91%) | 79 (85%) |
| Non-white | 9 (23%) | 5 (9%) | 14 (15%) |
| T-stage at enrollment | |||
| T1 | 14 (36%) | 20 (37%) | 34 (37%) |
| T2 | 19 (49%) | 28 (52%) | 47 (50%) |
| T3 | 6 (15%) | 6 (11%) | 12 (13%) |
| Smoking History | |||
| Never | 2 (5%) | 4 (7%) | 6 (6%) |
| Former | 25 (64%) | 39 (72%) | 64 (69%) |
| Current | 8 (21%) | 8 (15%) | 16 (17%) |
| Unknown | 4 (10%) | 3 (6%) | 7 (8%) |
| Pack Years (including non-smokers as 0) | |||
| Median | 39 | 34 | 35 |
| Min - Max | 0 - 110 | 0 - 136 | 0 - 136 |
| Q1 - Q3 | 30 - 60 | 8.5 - 53 | 15 - 54 |
| ECOG performance status | |||
| 0 | 31 (84%) | 42 (78%) | 73 (80%) |
| 1 | 6 (16%) | 12 (22%) | 18 (20%) |
| # Clinically or Pathologically + N2 Nodes @ Diagnosis | |||
| Median | 1 | 1 | 1 |
| Min - Max | 1 - 4 | 1 - 4 | 1 - 4 |
| Q1 - Q3 | 1 - 2 | 1 - 2 | 1 - 2 |
| Tumor Location | |||
| RUL | 18 (46%) | 26 (48%) | 44 (47%) |
| RML | 4 (10%) | 4 (7%) | 8 (9%) |
| RLL | 6 (15%) | 11 (20%) | 17 (18%) |
| LUL | 7 (18%) | 11 (20%) | 18 (19%) |
| LLL | 4 (10%) | 2 (4%) | 6 (6%) |
| Histology | |||
| Adenocarcinoma | 19 (49%) | 35 (65%) | 54 (58%) |
| Squamous | 7 (18%) | 13 (24%) | 20 (21%) |
| Other | 13 (33%) | 6 (11%) | 19 (20%) |
| FEV1 at Baseline | |||
| Median | 2.3 | 2.385 | 2.34 |
| Min - Max | 1.28 - 4.13 | 1.09 - 3.82 | 1.09 - 4.13 |
| Q1 - Q3 | 1.98 - 2.93 | 2.06 - 2.91 | 2.06 - 2.92 |
| Institution Type | |||
| Community | 12 (31%) | 15 (28%) | 27 (29%) |
| Academic | 25 (64%) | 34 (63%) | 59 (63%) |
| VA | 2 (5%) | 5 (9%) | 7 (8%) |
| Panitumumab | |||
| No | 39 (100.0%) | 19 (35%) | 58 (62%) |
| Yes | 0 (0.0%) | 35 (65%) | 35 (38%) |
| pCR | |||
| No | 29 (74%) | 41 (76%) | 70 (75%) |
| Yes | 10 (26%) | 13 (24%) | 23 (25%) |
| Mediastinal Nodal Clearance | |||
| No | 9 (23%) | 17 (31%) | 26 (28%) |
| Yes | 30 (77%) | 37 (69%) | 67 (72%) |
Q1 = first quartile; Q3 = third quartile; ECOG PS, Eastern Cooperative Group performance status; pCR, Complete Response to Chemoradiation